Toggle Main Menu Toggle Search

ePrints

Browsing publications by Philip Berry

Newcastle AuthorsTitleYearFull text
Dr Anastasia Hepburn
Laura Wilson
Evangelia Kounatidou
Amy Barnard
Philip Berry
et al.
Correction: The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance (Oncogene, (2019), 10.1038/s41388-019-0712-y)2019
Professor Gareth Veal
Philip Berry
Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste2019
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Calum Kirk
Dr Katrina Wood
et al.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma2019
Dr Anastasia Hepburn
Laura Wilson
Evangelia Kounatidou
Amy Barnard
Philip Berry
et al.
The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance2019
Philip Berry
Cancer-related health behaviours of young people not in education, employment or training ('NEET'): a cross-sectional study2018
Monique Zangarini
Philip Berry
Professor Gareth Veal
Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts2018
Dr Lynsey McKenzie
Hasan Issa
Sandeep Potluri
Dr Helen Blair
Asmida Isa
et al.
The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation2018
Dr Sally Coulthard
Sarah McGarrity
Dr Kiran Sahota
Philip Berry
Dr Chris Redfern
et al.
Three Faces of Mercaptopurine Cytotoxicity in vitro: Methylation, Nucleotide Homeostasis and Deoxythioguanosine in DNA2018
Dr Sally Coulthard
Philip Berry
Sarah McGarrity
Dr Chris Redfern
Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone2017
Monique Zangarini
Philip Berry
Julieann Sludden
Professor Gareth Veal
Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma2017
1234